The close focus of Europe on AI investments on the health of half of its population is left without prejudice. Since risk capital is disproportionately flooded into the AI sector, the health innovation in health – the definition of the essential infrastructure – is again becoming scrap.
In 2021 the global FemTech investment reached its peak € 1.89 billion € Before you fall to just 1.1 billion euros next year, you made you head across AI Several factors contributed to this decline – wider market conditions, comprehensive investorisikomaters and maturation of the natural sector. However, the increase in AI financing emerges with a jump in FemTech investments in serious problems with capital allocation.
In 2023, European FemTech conquered a mere € 164 million of € 8.3 billion in Healthtech financing. In the meantime, US FemTech startups have collected over the pond 4.5 billion € Since 2019, unless Europe has now taken, the AI boom could be the already acute health crisis – and reset to a sector that we once led worldwide.
Today, 44% Despite a projections, no funds have increased from European FemTech startups 30 billion € The European FemTech market until 2032. The separation between opportunities and investments is astonishing.
This pattern is repeated via the ecosystem. Talented founders with proven solutions for endometriosis, menopause, fertility and health of mothers are overlooked. These are companies that have a huge market and offer high returns. However, you have difficulty attention to the latest, the most shiny all-purpose-Ki startup that comes across investor writing tables.
TNW City Coworking Space – where your best work happens
A area of work for growth, cooperation and endless networking opportunities in the heart of technology.
The Iland Future Health problems, FemTech founders – who have often already diagnosed existing Crises and built work solutions – fight for basic financing.
This is far from an anti-Ai argument many of us FemTech companies build up useful AI applications for the health of women. However, the tunnel vision of investors for general AI platforms leaves special health solutions according to remains.
There are also human costs here. The fact that capital and talent femtech deals is not only a missed investment option, but also a case of health of women. The average woman with endometriosis is waiting seven years for a diagnosis. Up to 70% of women With the polycystic ovarian syndrome (PCOS), they are not diagnosed worldwide. While these numbers reflect a global crisis. European FemTech solutions are not only of crucial importance for women in Europe, but can also deal with critical topics worldwide.
Far from solving these problems, it often tightens them without creating the specialization of the healthcare system. Research of UNESCO And Un -womenIt shows, among other things, that AI and LLMS are based on biased data, the medical assumptions for the male definition constantly maintain. This can lead to misdiagnoses, delayed treatment and years of unnecessary suffering.
In 2024 only founding teams only make up for women. significant proportion Get from FemTech founders – Only 2% global VC financing, compared to 84% for only male financing teams. The inequality left critical gaps in the health infrastructure for women. When someone with a purely female team of senior team who has raised one of the largest FemTech rounds in Europe in Europe this year, I know first-hand how brutal the current fundraising process is.
Europe’s FemTech future
In the past, Europe was a leading innovation of women’s health, characterized by significant public investments, pioneer startups and important political leadership in gender-sensitive health care. The region houses other FemTech pioneers such as Flo Health (UK), Note (Germany), natural cycles (Sweden) and Ava (Switzerland). But this advantage disappears.
The AI bladder will continue your unpredictable journey. Femtech, on the other hand, – defined as a category of products, services and software that meets the health and needs of women – does not go anywhere. The failure of Europe to recognize this is that the risk of going back to other regions will maintain diversified health -tech investments.
To fix the problem, we need a change. Recognize that FemTech is not a niche – it serves 50% of the world’s population. Hine another market of 3.9 billion customers and watch VCS Stampede. Adjust the health of women to the same investors and watch how to check your phones.
Overall, investors have to reconcile their AI investments with proven health solutions. It’s not just about constructing socially responsible portfolios – there is a huge, underserved market that is only waiting to be activated.
That means building funds that are dedicated to FemTech and are supported more Women led Investment teams that actually understand the respective problems. Far from checking only boxes, women-guided teams can understand femtech investment opportunities much better. UNESCO – offer a familiarity with the problems and solutions of the sector that are often missing to your male colleagues. The evidence is clear: in Europe countries with committed investor networks see female angel networks 27% Higher financing rates for women for women.
Political decision -makers also have to reform F&E finance structures to ensure that the health of women receives proportional investments. If public financing flows disproportionately to AI research, this signals that women’s health remains a secondary problem.
Europe can be leading both in AI and Femtech – these are far from excluding each other. The goal is not to slow the AI investment, but to ensure that Femtech receives its appropriate share of capital allocation. If Femtech is not postponed by the niche to a necessity, the story shows us that it will stay on the track because it has long been critically overlooked, underfunded and examined.
FemTech is not another bladder that is waiting for burst – women’s health needs do not disappear when VCS jumps into the next Hype train. The choice that we now meet determines whether women still have collateral damage in every new investment frenzy.
If Europa Femtech continues to ignore, the price will not only be declined. Women who are waiting for years will be a simple diagnosis, life with untreated conditions and suffering from problems that we can already prevent. Although women live longer than men, we spend out 25% more of our life in poor health. This is a cost that investors cannot continue.
Comments are closed.